Observational studyBMC cardiovascular disorders2025
HATCH score associated with new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe HATCH score, a new atrial fibrillation (AF) risk model, has drawn wide attention. However, in patients with ST-segment elevation myocardial infarction (STEMI), the relationship between the HATCH score and NOAF remains unclear. This study aimed to assess the association between HATCH score and new-onset AF (NOAF) after percutaneous coronary intervention (PCI) in STEMI patients.
methodsThis single-center retrospective observation consecutively selected patients diagnosed with STEMI who underwent primary PCI. All patients received continuous electrocardiogram monitoring during hospitalization (≥ 36 h). HATCH score was calculated based on hypertension (1 point), age > 75 years (1 point), stroke or TIA (2 point), COPD (1 point), and HF (2 point).
resultsA total of 774 patients were included in this study, of whom 65.37% were male, with a mean age of 63.53 ± 13.11 years, 73 patients (9.43%) developed NOAF. ROC curve demonstrated that the AUC of the HATCH score was 0.731, the cut - off value was 2.5. Multivariate logistic regression analysis indicated that the HATCH score (OR = 1.66, 95% CI: 1.41-1.95, P < 0.001) or HATCH score ≥ 3 (OR = 4.10, 95% CI: 2.39-7.02, P < 0.001) was an independent risk predictor for NOAF. The RCS analysis revealed a linear correlation between the HATCH score and NOAF (P for overall < 0.001).
conclusionsElevated HATCH score is an independent risk factor for the development of NOAF after PCI in STEMI patients. There was a linear dose-response relationship between HATCH score and NOAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.